PD-L1 expression was assessed using the 22C3 pharmDx assay, and the tumor proportion scores (TPS) were available for 41 patients, of whom 14 (33.3%) demonstrated high PD-L1 expression (TPS ≥ 50%). The gene discussed is CD274; the disease is neoplasm.